# reload+after+2024-01-22 13:47:09.227492
address1§300 Park Avenue
address2§2nd Floor
city§New York
state§NY
zip§10022
country§United States
phone§646 293 2100
website§https://seelostherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.
fullTimeEmployees§16
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Raj  Mehra J.D., Ph.D.', 'age': 63, 'title': 'Founder, Chairman, CEO & President', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 854732, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael J. Golembiewski', 'age': 51, 'title': 'Chief Financial Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 454827, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kimberly  Farrand', 'title': 'Senior Director of Clinical Development & Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Anthony  Marciano', 'title': 'Chief Communications Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Gopal  Krishna Ph.D.', 'title': 'Head of Manufacturing & Technical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Tim  Whitaker M.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Karen  Fusaro', 'title': 'Senior VP & Head of Clinical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.867
priceToSalesTrailing12Months§8.435986
currency§USD
dateShortInterest§1702598400
forwardEps§-9.3
exchange§NCM
quoteType§EQUITY
shortName§Seelos Therapeutics, Inc.
longName§Seelos Therapeutics, Inc.
firstTradeDateEpochUtc§924528600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f2cc18eb-3998-3582-b235-fcd39ce72b88
gmtOffSetMilliseconds§-18000000
targetHighPrice§120.0
targetLowPrice§120.0
targetMeanPrice§120.0
targetMedianPrice§120.0
recommendationMean§1.0
recommendationKey§strong_buy
numberOfAnalystOpinions§1
quickRatio§0.079
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
